Lonza: Sign Strategic Long-Term Manufacturing Agreement To Secure Supply Of Rucaparib With Clovis Oncology.

27 Oct 2016 13:35

First dedicated small-molecule manufacturing line to be constructed in Visp, Switzerland. New line will be operational in 2019, providing Clovis dedicated product supply for rucaparib until 2025. Innovative operating model allows coverage of a range of demand scenarios and secures supply...

Attachments: